CinCor Reports Second Quarter Financial Results and Provides Corporate Update
WALTHAM, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced financial results for the second quarter ended June 30, 2022 and provided a corporate update.
- We look forward to continuing the clinical momentum with topline data for HALO expected to read out in the second half of 2022.
- In July 2022, CinCor completed enrollment in the Phase 2 HALO trial with 249 patients randomized.
- CinCor, founded in 2018, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases.
- CinCor undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.